You are viewing the site in preview mode

Skip to main content

Table 2 Multivariable linear regression analysis to evaluate the therapeutic effect of mirabegron on the fourth-year HAM-BDSS

From: Clinical course of neurogenic bladder dysfunction in human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: a nationwide registry study in Japan

Variable Model 1 Model 2 Model 3
β 95%CI p value β 95%CI p value β 95%CI p value
Total score          
Mirabegron started in 4th year − 5.86 − 9.15, − 2.57 0.001 − 5.79 − 9.10, − 2.49 0.001 − 5.82 − 9.13, − 2.50 0.001
HAM-BDSS (3rd year) 0.88 0.80, 0.96 < 0.001 0.87 0.79, 0.95 < 0.001 0.86 0.78, 0.95 < 0.001
Age (1-year increase) – – – − 0.02 − 0.09, 0.05 0.592 − 0.02 − 0.08, 0.05 0.673
Sex (female vs. male) – – – − 0.93 − 2.61, 0.77 0.281 − 0.79 − 2.54, 0.96 0.373
α1 adrenergic-receptor antagonists – – – – – – 1.80 − 0.45, 4.03 0.115
Cholinergic agonists – – – – – – − 1.75 − 5.44, 1.94 0.350
Anticholinergics – – – – – – 0.37 − 1.97, 2.71 0.752
Storage symptom score          
Mirabegron started in 4th year − 2.73 − 5.06, − 0.41 0.022 − 2.64 − 4.97, − 0.32 0.026 − 2.72 − 5.02, − 0.42 0.021
HAM-BDSS (3rd year) 0.81 0.69, 0.92 < 0.001 0.79 0.67, 0.90 < 0.001 0.79 0.68, 0.91 < 0.001
Age (1-year increase) – – – –0.002 − 0.05, 0.05 0.926 0.00 − 0.05, 0.05 0.994
Sex (female vs. male) – – – − 0.94 − 2.11, 0.23 0.115 − 1.04 − 2.24, 0.16 0.088
α1 adrenergic-receptor antagonists – – – – – – 0.85 − 0.68, 2.38 0.275
Cholinergic agonists – – – – – – − 1.45 − 4.00, 1.09 0.261
Anticholinergics – – – – – – 1.44 − 0.17, 3.05 0.079
Voiding symptom score          
Mirabegron started in 4th year − 2.83 − 4.81, − 0.87 0.005 − 2.83 − 4.82, − 0.84 0.006 − 2.81 − 4.80, − 0.82 0.006
HAM-BDSS (3rd year) 0.92 0.85, 0.99 < 0.001 0.92 0.84, 0.99 < 0.001 0.91 0.83, 0.99 < 0.001
Age (1-year increase) – – – − 0.01 − 0.05, 0.03 0.626 − 0.01 − 0.05, 0.03 0.662
Sex (female vs male) – – – − 0.02 − 1.04, 0.99 0.963 0.22 − 0.83, 1.26 0.679
α1 adrenergic-receptor antagonists – – – – – −  0.82 − 0.53, 2.17 0.232
Cholinergic agonists – – – – – – − 0.15 − 2.37, 2.07 0.893
Anticholinergics – – – – – – − 1.06 − 2.46, 0.35 0.139
  1. Multivariable linear regression analysis adjusted by the third-year HAM-BDSS: model 1 included the third-year HAM-BDSS and initiation of mirabegron in the fourth year; model 2 was model 1 plus adjustments for age and sex; model 3 was model 2 plus an adjustment for other medications for urinary symptoms
  2. HAM-BDSS, HAM/TSP-bladder dysfunction symptom score
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172